178 related articles for article (PubMed ID: 21496446)
1. Early therapy evaluation of combined cetuximab and irinotecan in orthotopic pancreatic tumor xenografts by dynamic contrast-enhanced magnetic resonance imaging.
Kim H; Folks KD; Guo L; Sellers JC; Fineberg NS; Stockard CR; Grizzle WE; Buchsbaum DJ; Morgan DE; George JF; Zinn KR
Mol Imaging; 2011 Jun; 10(3):153-67. PubMed ID: 21496446
[TBL] [Abstract][Full Text] [Related]
2. Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging.
Kim H; Morgan DE; Buchsbaum DJ; Zeng H; Grizzle WE; Warram JM; Stockard CR; McNally LR; Long JW; Sellers JC; Forero A; Zinn KR
Cancer Res; 2008 Oct; 68(20):8369-76. PubMed ID: 18922909
[TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.
Hotz B; Keilholz U; Fusi A; Buhr HJ; Hotz HG
Gastric Cancer; 2012 Jul; 15(3):252-64. PubMed ID: 22011788
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG PET/CT imaging detects therapy efficacy of anti-EMMPRIN antibody and gemcitabine in orthotopic pancreatic tumor xenografts.
Shah N; Zhai G; Knowles JA; Stockard CR; Grizzle WE; Fineberg N; Zhou T; Zinn KR; Rosenthal EL; Kim H
Mol Imaging Biol; 2012 Apr; 14(2):237-44. PubMed ID: 21494920
[TBL] [Abstract][Full Text] [Related]
5. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for the Prediction of Monoclonal Antibody Tumor Disposition.
Bordeau BM; Polli JR; Schweser F; Grimm HP; Richter WF; Balthasar JP
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054865
[TBL] [Abstract][Full Text] [Related]
6. Cetuximab and irinotecan interact synergistically to inhibit the growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice.
Kim S; Prichard CN; Younes MN; Yazici YD; Jasser SA; Bekele BN; Myers JN
Clin Cancer Res; 2006 Jan; 12(2):600-7. PubMed ID: 16428506
[TBL] [Abstract][Full Text] [Related]
7. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers.
Cardillo TM; Govindan SV; Sharkey RM; Trisal P; Arrojo R; Liu D; Rossi EA; Chang CH; Goldenberg DM
Bioconjug Chem; 2015 May; 26(5):919-31. PubMed ID: 25915780
[TBL] [Abstract][Full Text] [Related]
8. Dual combination therapy targeting DR5 and EMMPRIN in pancreatic adenocarcinoma.
Kim H; Zhai G; Samuel SL; Rigell CJ; Umphrey HR; Rana S; Stockard CR; Fineberg NS; Zinn KR
Mol Cancer Ther; 2012 Feb; 11(2):405-15. PubMed ID: 22203731
[TBL] [Abstract][Full Text] [Related]
9. Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth.
Bangard C; Gossmann A; Papyan A; Tawadros S; Hellmich M; Bruns CJ
Int J Cancer; 2005 Mar; 114(1):131-8. PubMed ID: 15523683
[TBL] [Abstract][Full Text] [Related]
10. Integration of novel agents in the treatment of colorectal cancer.
Iqbal S; Lenz HJ
Cancer Chemother Pharmacol; 2004 Sep; 54 Suppl 1():S32-9. PubMed ID: 15309512
[TBL] [Abstract][Full Text] [Related]
11. Dynamic contrast-enhanced MRI evaluates the early response of human head and neck tumor xenografts following anti-EMMPRIN therapy with cisplatin or irradiation.
Kim H; Hartman YE; Zhai G; Chung TK; Korb ML; Beasley TM; Zhou T; Rosenthal EL
J Magn Reson Imaging; 2015 Oct; 42(4):936-45. PubMed ID: 25704985
[TBL] [Abstract][Full Text] [Related]
12. Monitoring the effects of anti-angiogenesis on the radiation sensitivity of pancreatic cancer xenografts using dynamic contrast-enhanced computed tomography.
Cao N; Cao M; Chin-Sinex H; Mendonca M; Ko SC; Stantz KM
Int J Radiat Oncol Biol Phys; 2014 Feb; 88(2):412-8. PubMed ID: 24411612
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
Mudd SR; Holich KD; Voorbach MJ; Cole TB; Reuter DR; Tapang P; Bukofzer G; Chakravartty A; Donawho CK; Palma JP; Fox GB; Day M; Luo Y
Mol Imaging Biol; 2012 Oct; 14(5):617-24. PubMed ID: 22167582
[TBL] [Abstract][Full Text] [Related]
14. (99)mTc-(CO)(3) His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab.
Vangestel C; Van de Wiele C; Van Damme N; Staelens S; Pauwels P; Reutelingsperger CP; Peeters M
J Nucl Med; 2011 Nov; 52(11):1786-94. PubMed ID: 22045708
[TBL] [Abstract][Full Text] [Related]
15. Dynamic contrast-enhanced magnetic resonance imaging rapidly indicates vessel regression in human squamous cell carcinomas grown in nude mice caused by VEGF receptor 2 blockade with DC101.
Kiessling F; Farhan N; Lichy MP; Vosseler S; Heilmann M; Krix M; Bohlen P; Miller DW; Mueller MM; Semmler W; Fusenig NE; Delorme S
Neoplasia; 2004; 6(3):213-23. PubMed ID: 15153333
[TBL] [Abstract][Full Text] [Related]
16. MR Imaging Biomarkers to Monitor Early Response to Hypoxia-Activated Prodrug TH-302 in Pancreatic Cancer Xenografts.
Zhang X; Wojtkowiak JW; Martinez GV; Cornnell HH; Hart CP; Baker AF; Gillies R
PLoS One; 2016; 11(5):e0155289. PubMed ID: 27227903
[TBL] [Abstract][Full Text] [Related]
17. Vascular normalization in orthotopic glioblastoma following intravenous treatment with lipid-based nanoparticulate formulations of irinotecan (Irinophore C™), doxorubicin (Caelyx®) or vincristine.
Verreault M; Strutt D; Masin D; Anantha M; Yung A; Kozlowski P; Waterhouse D; Bally MB; Yapp DT
BMC Cancer; 2011 Apr; 11():124. PubMed ID: 21477311
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal PET Imaging to Monitor Treatment Efficacy by Liposomal Irinotecan in Orthotopic Patient-Derived Pancreatic Tumor Models of High and Low Hypoxia.
Ventura M; Bernards N; De Souza R; Fricke IB; Hendriks BS; Fitzgerald JB; Lee H; Klinz SG; Zheng J
Mol Imaging Biol; 2020 Jun; 22(3):653-664. PubMed ID: 31482415
[TBL] [Abstract][Full Text] [Related]
19. Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer.
DeRosier LC; Buchsbaum DJ; Oliver PG; Huang ZQ; Sellers JC; Grizzle WE; Wang W; Zhou T; Zinn KR; Long JW; Vickers SM
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5535s-5543s. PubMed ID: 17875786
[TBL] [Abstract][Full Text] [Related]
20. Dynamic contrast enhanced magnetic resonance imaging of an orthotopic pancreatic cancer mouse model.
Kim H; Samuel S; Totenhagen JW; Warren M; Sellers JC; Buchsbaum DJ
J Vis Exp; 2015 Apr; (98):. PubMed ID: 25938718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
